Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash & Current Investments (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cash & Current Investments for 2 consecutive years, with $10.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments fell 92.82% to $10.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.4 million, a 92.82% decrease, with the full-year FY2024 number at $126.9 million, changed N/A from a year prior.
  • Cash & Current Investments was $10.4 million for Q3 2025 at Pyxis Oncology, down from $88.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $157.0 million in Q1 2024 to a low of $10.4 million in Q3 2025.